Analyst Price Targets — MRK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 11:05 am | Mohit Bansal | Wells Fargo | $150.00 | $116.22 | StreetInsider | Merck (MRK) PT Raised to $150 at Wells Fargo |
| February 24, 2026 9:04 pm | Trung Huynh | RBC Capital | $142.00 | $123.93 | StreetInsider | RBC Capital Starts Merck (MRK) at Outperform |
| February 13, 2026 1:30 pm | James Shin | Deutsche Bank | $150.00 | $121.53 | TheFly | Merck upgraded to Buy from Hold at Deutsche Bank |
| February 4, 2026 12:48 pm | Asad Haider | Goldman Sachs | $133.00 | $115.86 | TheFly | Merck price target raised to $133 from $120 at Goldman Sachs |
| February 4, 2026 12:46 pm | — | BMO Capital | $135.00 | $115.86 | TheFly | Merck price target raised to $135 from $130 at BMO Capital |
| February 4, 2026 11:52 am | — | Bernstein | $100.00 | $115.86 | TheFly | Merck price target raised to $100 from $95 at Bernstein |
| February 3, 2026 6:18 pm | — | Scotiabank | $136.00 | $116.37 | TheFly | Merck price target raised to $136 from $120 at Scotiabank |
| January 27, 2026 12:22 pm | — | Cantor Fitzgerald | $116.00 | $107.40 | TheFly | Merck price target raised to $116 from $83 at Cantor Fitzgerald |
| January 8, 2026 11:41 am | — | Wolfe Research | $135.00 | $108.59 | TheFly | Merck upgraded to Outperform from Peer Perform at Wolfe Research |
| January 7, 2026 1:15 pm | — | UBS | $130.00 | $110.96 | TheFly | Merck price target raised to $130 from $105 at UBS |
Latest News for MRK
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced RCC.
In the closing of the recent trading day, Merck (MRK) stood at $117.1, denoting a -1.65% move from the preceding trading day.
MRK gains EU approval for Enflonsia to prevent RSV in infants during their first season.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapy, each in combination with Padcev®…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.